- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04124419
Safety and Efficacy of Combined EMS and RF Treatments
Baseline Controlled Study to Evaluate the Safety and Efficacy of Combined EMS and RF Treatments for Non-Invasive Circumference Reduction and Skin Tightening
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nevada
-
Reno, Nevada, United States, 89511
- Avance Plastic Surgery Institute
-
-
New York
-
New York, New York, United States, 10019
- BodySculpt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Signed informed consent to participate in the study.
- Female and male subjects,18 - 65 years of age at the time of enrolment
- BMI≤ 30
- If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
- In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
- General good health confirmed by medical history and skin examination of the treated area.
- Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
- The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.
Exclusion Criteria:
- - Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
- Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
- Intra-dermal or superficial sub-dermal areas that have been injected with HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
- Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.
- Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
- Pregnancy and nursing.
- Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, autoimmune disorders or use of immunosuppressive medications.
- Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
- Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
- Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
- History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
- History of bleeding coagulopathies, or use of anticoagulants in the last 10 days.
- Any surgical procedure in the treatment area within the last 6 months or before complete healing.
- Having received treatment with light, laser, RF, or other devices in the treated area within 3 months, or before complete healing.
- Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
- As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
|
EMS and RF Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in circumference reduction
Time Frame: 1 month, 3 month, 6 months
|
statistical difference in circumference reduction between Control (baseline measurement) and three points of follow-up measurement: 4 weeks (1Month) 12 weeks (3Month) and 24 weeks (6 months) following the last Tx session.
|
1 month, 3 month, 6 months
|
Change in skin appearance
Time Frame: 1 month, 3 month, 6 months
|
Improvement in skin appearance comparing pre and at 1, 3 months and 6 months post last treatment photographs (as assessed by blinded investigators): Success is defined by correct identification of the pre and post-treatment photos as demonstrated in at least 70% or greater of patients completed the treatment at 1 month, 3 months, and 6 months post-treatment. |
1 month, 3 month, 6 months
|
Change in abdomen area appearance assessed by 3D Photographic analysis
Time Frame: 1 month, 3 month, 6 months
|
3D Photographic analysis will be conducted using QuantifiCare System at follow up visits and compared to the baseline.
|
1 month, 3 month, 6 months
|
Change in abdomen area appearance assessed by Investigator
Time Frame: 1 month, 3 month, 6 months
|
- Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference
|
1 month, 3 month, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Improvement assessment
Time Frame: 1 Month, 3 Months, 6 Months
|
Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference. |
1 Month, 3 Months, 6 Months
|
Subject satisfaction assessment
Time Frame: 1 month, 3 months, 6 months
|
Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows: +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed. |
1 month, 3 months, 6 months
|
Subject assessment of comfort
Time Frame: 1 month, 3 months, 6 months
|
Subject assessment of comfort will be filled out by subjects using a 5-point Likert scale, as follows: +2 = Very comfortable; +1 = Comfortable; 0 = Indifferent; -1 = uncomfortable; -2 = Pain. |
1 month, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DO608715A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-invasive Circumference Reduction
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
Syneron MedicalCompletedCircumference ReductionUnited States
-
Syneron CandelaUnknown
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
Erchonia CorporationTerminatedCircumference ReductionUnited States
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
UltraShapeUnknownReduction in Abdominal CircumferenceIsrael
-
InMode MD Ltd.Active, not recruitingCircumference Reduction of AbdomenUnited States
-
Alma Lasers Inc.Unknown
-
Yolo Medical Inc.CompletedReduction of the Waist CircumferenceUnited States
Clinical Trials on Treatment with Evolve System
-
Queen's UniversityCompletedDirect Costs Excluding Capital Equipment Purchase | Operator (Surgeon) Completed Questionnaire | Operative Parameters (Time, Bleeding Etc) | Complications (Post-op Retention, Bleeding, Re-admission to Hospital, Infection Etc) | 3 Month Efficacy Evaluation (Compared to Baseline) Using Validated...Canada
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain
-
Abbott Medical DevicesTerminated
-
Baylis Medical CompanyTerminatedChronic Sacroiliac Joint PainUnited States
-
Miramar LabsCompletedAxillary HyperhidrosisCanada
-
Siemens Healthcare QTCompletedFracture of Distal End of RadiusGermany
-
Stryker NeurovascularActive, not recruitingAneurysm, IntracranialUnited States, Canada, Australia
-
BTL Industries Ltd.WithdrawnFat BurnUnited States, Bulgaria
-
BTL Industries Ltd.WithdrawnFat BurnUnited States, Bulgaria